Elizabeth Hall–Meyers

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +6

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

Ellen Weisberg, Laurie Catley, Renee D. Wright et al. · Blood · 2006 · 106 citations · Full text

Medicine, Molecular Biology, Oncology +7

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 105 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +6

Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity

Ellen Weisberg, Renee D. Wright, Jingrui Jiang et al. · Gastroenterology · 2006 · 93 citations

Medicine, Oncology, Pharmacology +13

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells

Ellen Weisberg, Lolita Banerji, Renee D. Wright et al. · Blood · 2008 · 85 citations · Full text

Medicine, Oncology, Pharmacology +15